Evonetix expands to develop its desktop DNA synthesis platform
15,000 sq. ft of laboratory and office space will enable continued growth and development of the company’s integrated desktop platform for DNA synthesis.
Evonetix has moved to Coldham’s Business Park, Cambridge, UK. The new facility will enable the continued growth of the company as it continues in its mission to develop a desktop DNA synthesis platform based on its proprietary silicon chip.
Evonetix, previously based at Chesterford Research Park, now occupies 15,000 sq. ft at Coldham’s Business Park, comprising 8,000 sq. ft of fully fitted and equipped state-of-the art laboratory space and 7,000 sq. ft of office space all under one roof. This enables the company’s teams of physicists, electronics and software engineers, chemists, biologists and molecular biologists to work more closely together in a multidisciplinary approach to deliver the Evonetix mission. Headcount currently stands at 40, including 26 PhD biologists, physicists, chemists and engineers, and the company is currently looking to recruit further staff, including biophysicists, electronics and protein engineers.
The company’s silicon chip is made by MEMS processing and controls the synthesis of DNA at many thousands of independently controlled reaction sites or ‘pixels’ on the chip surface in a highly parallel fashion. This is compatible with both chemical and enzymatic DNA synthesis. Following synthesis, strands are assembled on-chip into double-stranded DNA in a process that identifies and removes errors, enabling accuracy, scale and speed that is several orders of magnitude better than conventional approaches.
Dr Tim Brears, Evonetix CEO, said: “Synthetic biology has the potential to solve some of the world’s most intractable problems, but we require innovation in gene synthesis to accelerate progress. Our new office and lab space will enable integration of our teams of specialists to support the development and delivery of our highly parallel desktop platform, which will be available to every researcher to accelerate their ability to use biology on a scale not currently possible.”
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...